Auxilium’s Dupuytren's treatment gets FDA priority

Auxilium Pharmaceuticals, Inc. today said the U.S. Food and Drug Administration granted priority review status to its biologics license application for Xiaflex to treat Dupuytren's contracture.

The FDA is expected to take action on the application by Aug. 28.

Dupuytren's contracture is a disease that causes collagen to build up in hands and impairs patients' ability to straighten their fingers.

The Malvern company said Xiaflex breaks down excess collagen.    - Miriam Hill